Celgene invests $100M, gains option to buy Acetylon

07/29/2013 | Boston Globe (tiered subscription model), The

Celgene agreed to invest $100 million in Acetylon Pharmaceuticals in exchange for an exclusive option to purchase the Boston drugmaker at a price from $500 million to $1.1 billion contingent on certain milestones. Acetylon will use some of the funding to further develop ACY-1215, its lead drug candidate for myeloma. Celgene took a $15 million equity stake in Acetylon last year.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN